Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...

The median length of survival for individuals with ILD who completed pulmonary rehabilitation was 6.1 years vs 4.7 years in the control group. Pulmonary rehabilitation (PR) may improve survival at 5 ...

Lung cancer has become a major health concern in India, attributed to air pollution, smoking, and genetic factors. Early ...

Molecular profiling and genetic testing have revolutionised lung cancer treatment, says a doctor. They have enabled targeted ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase 3 study.

Scientists uncover an enzyme that boosts cancer cell metabolism to fuel growth. The enzyme, GUK1, supports metabolism in cancer cells to help tumors grow.